Literature DB >> 8122375

Characterization of filoviruses based on differences in structure and antigenicity of the virion glycoprotein.

H Feldmann1, S T Nichol, H D Klenk, C J Peters, A Sanchez.   

Abstract

Eight different filovirus isolates, representing major episodes of filovirus hemorrhagic disease, were propagated for structural and antigenetic analyses of their glycoprotein (GP). Carbohydrate analysis revealed that N- and O-glycosylation are features of filovirus GPs. Oligosaccharide side chains differed in their sialylation pattern and seemed to be cell line-dependent. Marburg virus (MBG) isolates are clearly distinguished from Ebola (EBO) and Reston viruses by a lack of terminal sialic acids when propagated in E6 and MA-104 cells. It was also determined that GP-specific antisera failed to show any cross-reactivity between MBG isolates and other filoviruses. These data, together with prior findings, indicate that the genus Filovirus can be divided into a MBG group and EBO group.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8122375     DOI: 10.1006/viro.1994.1147

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  52 in total

1.  Functional importance of the coiled-coil of the Ebola virus glycoprotein.

Authors:  S Watanabe; A Takada; T Watanabe; H Ito; H Kida; Y Kawaoka
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

2.  Characterization of the glycoproteins of Crimean-Congo hemorrhagic fever virus.

Authors:  Angela J Sanchez; Martin J Vincent; Stuart T Nichol
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

3.  Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations.

Authors:  Jens H Kuhn; Stephan Becker; Hideki Ebihara; Thomas W Geisbert; Karl M Johnson; Yoshihiro Kawaoka; W Ian Lipkin; Ana I Negredo; Sergey V Netesov; Stuart T Nichol; Gustavo Palacios; Clarence J Peters; Antonio Tenorio; Viktor E Volchkov; Peter B Jahrling
Journal:  Arch Virol       Date:  2010-10-30       Impact factor: 2.574

4.  Functional mapping of the nucleoprotein of Ebola virus.

Authors:  Shinji Watanabe; Takeshi Noda; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

5.  Expression of an immunogenic Ebola immune complex in Nicotiana benthamiana.

Authors:  Waranyoo Phoolcharoen; Seong H Bhoo; Huafang Lai; Julian Ma; Charles J Arntzen; Qiang Chen; Hugh S Mason
Journal:  Plant Biotechnol J       Date:  2011-02-01       Impact factor: 9.803

Review 6.  Ebola virus pathogenesis: implications for vaccines and therapies.

Authors:  Nancy Sullivan; Zhi-Yong Yang; Gary J Nabel
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

7.  Inhibition of Marburg virus budding by nonneutralizing antibodies to the envelope glycoprotein.

Authors:  Masahiro Kajihara; Andrea Marzi; Eri Nakayama; Takeshi Noda; Makoto Kuroda; Rashid Manzoor; Keita Matsuno; Heinz Feldmann; Reiko Yoshida; Yoshihiro Kawaoka; Ayato Takada
Journal:  J Virol       Date:  2012-10-03       Impact factor: 5.103

8.  The lack of maturation of Ebola virus-infected dendritic cells results from the cooperative effect of at least two viral domains.

Authors:  Ndongala M Lubaki; Philipp Ilinykh; Colette Pietzsch; Bersabeh Tigabu; Alexander N Freiberg; Richard A Koup; Alexander Bukreyev
Journal:  J Virol       Date:  2013-04-24       Impact factor: 5.103

9.  Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species.

Authors:  Lisa E Hensley; Sabue Mulangu; Clement Asiedu; Joshua Johnson; Anna N Honko; Daphne Stanley; Giulia Fabozzi; Stuart T Nichol; Thomas G Ksiazek; Pierre E Rollin; Victoria Wahl-Jensen; Michael Bailey; Peter B Jahrling; Mario Roederer; Richard A Koup; Nancy J Sullivan
Journal:  PLoS Pathog       Date:  2010-05-20       Impact factor: 6.823

Review 10.  Post-exposure treatments for Ebola and Marburg virus infections.

Authors:  Robert W Cross; Chad E Mire; Heinz Feldmann; Thomas W Geisbert
Journal:  Nat Rev Drug Discov       Date:  2018-01-29       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.